FAQ - Cystadenocarcinoma, Papillary
(Powered by Yahoo! Answers)

How common is Giant Papillary Conjunctivitis in patients who have never worn contacts?

I was diagnosed with Giant Papillary Conjunctivitis a week and a half ago. Symptoms began a couple weeks before that. I have never ever worn contact lenses. I'm just wondering how common this is among non-contact-wearers?

A similar condition can be seen in severe atopic conjunctivitis.
GPC is a reaction to protein deposits on foreign objects on the eye. Besides soft lenses, rigid lenses and hard lenses one can see it from prosthetic eyes ("glass eyes"-really plastic) and foreign bodies such as sutures following eye surgery.
Another possibility is you were misdiagnosed when in fact you might have an infectious conjunctivitis with a lot of lid conjunctival reaction.  (+ info)

what are the next steps in papillary thyroid cancer reoccurance?

i had papillary thyroid cancer 2 years ago. it was removed with a total thyroidectomy. i had radioactive iodine treatment after surgery and i've been tested here and there since. i just had a routine ultrasound where they found a suspicious lymph node. i'm scheduled for a FNA (fine needle) my question is, if the results come back positive for a reoccurance, what will ne my next step? more surgery? more RAI? chemo?

When I had a recurrence in my lymph nodes I did a low dose RAI followed by a body scan to see where it traveled to and since it was only in 4 of my lymph nodes they removed 11 and then I went off my meds for awhile did another small dose body scan followed by a high dose RAI and body scan but im sure every doctor does things different but that was my experience with it and now I am cancer free again.
I dont think chemo is the treatment of choice because the iodine is move effective on the thyroid and its safer i believe  (+ info)

Why would a thyroid tumor have both papillary and follicular cells?

My friend was just dx'd w/ thyroid cancer. She had surgery to remove the 1.2 centimeter tumor in the middle of her thyroid. 3 of the 6 lymph nodes that were taken were found to also have cancer. Why would her tumor be both papillary AND follicular? What does that mean for her?

Thyroid cancer is not rare. It's the easiest to cure. I am surprised they did not take all the thyroid. All this means is the thyroid cancer went into the nodes. I had thyroid cancer the same kind with lymph nodes also cancer seeded with thyroid. I was given after surgery, radio-active iodine in large doses to get rid of all thyroid cancer several times. And yes you are radio-active to others. You stay away from children, women who are prego. It's not as bad as you think I am still here and trust my doctor to do his best for me. I sure will be praying for your friend. Now smile people do care.  (+ info)

Which is the place to get treatment for papillary thyroid cancer in India?


I am male, 30 years old. Which is the place to get treatment for papillary thyroid cancer in India and How much it cost?

Kindly Reply,
Cancer Fighter.

I don't have an answer, but I do have a site with more info and maybe they can help. www.thyca.org (thyroid cancer survivors for america)  (+ info)

Can anyone please share their experience or advice regarding papillary carcinoma?

My mother, aged 69, had a 2 centimeter invasive papillary carcinoma removed in a lumpectomy recently. Thankfully, there was no evidence of any of the lymph nodes involved.

Of course, we are very concerned, and would like to know what are the experiences of those who have been diagnosed with papillary carcinoma. What treatments did you undergo? For how long? What were the side effects/possible contraindications and outcome of your treatments? How did you choose your oncologist?

Any advice or details you could give us would be sincerely appreciated.

I don’t know how many responses you are going to get, as papillary carcinoma of the breast is fairly rare and the information you provide is a little vague. Breast cancer treatment depends on the stage of the disease, the grade and if the hormone receptors are negative or positive none of which you mention. From what you stated your mom is a stage I, right at the edge of a stage IIA.

She is very luck that it was caught this early as they grow more rapidly than others and when found the tumors are often larger than your mother’s. The lymph nodes are usually negative, but hopefully a sentinel node biopsy was done to be sure. This type of cancer tends to happen most often in black women. For some reason we do not yet understand cancer in general is more aggressive in black patients, so if your mother is black I would have this treated as aggressively as possible to be on the safe side.

I firmly believe when faced with a significant medical decision you should get at least 2 opinions. If your mom lives in a less populated area she may want to get an opinion from the closest teaching facility as they tend to be involved in the most unusual cases and the cutting edge treatment. It may be too far to travel for treatment, but they can create a treatment plan that can be followed locally. Hope this helps. Best wishes to you both.

  (+ info)

is thyroidectomy the ONLY way to determine if a papillary lesion / follicular neoplasm is benign or malignant?

My wife recently underwent FNAB for the thyroid gland and the findings were:
Suggest thyroidectomy for a definitive diagnosis.
Microscopic Description:
Smears disclose a fairly cellular aspirate composed of cohesive clusters of follicular cells, in attempt to form acini and short papillary fronds. The cells show vesicular nuclei, with focal areas of pleomorphism. The background is hemorrhagic containing thin colloid materials and few mixed leukocytes.

I really would like to know if the it is benign or malignant but is there any other way besides invasive surgery? Thanks a lot in advance for all the answers and help.

If FNAB demonstrate follicular neoplasm , we must perform thyroid lobectomy for determining if it's malignant or not , and regarding to this , we will design the further definite and main operation .

There is no way other than this yet .

In some situations , we can perform total thyroidectomy as a plan to determine the permanent pathology at first ( there is several indications : old patients , mass more than 4 cm , ... ) .

But about Papillary neoplasm it's somewhat different : we can plan for a definite operation , also with a FNAB .  (+ info)

What is the treatment of choice for papillary carcinoma thyroid discovered in a hemi thyroidectomy specimen?

We operated on a patient whose FNAC was a colloid nodule.. She was a case of Solitary Thyroid nodule.. Hemithyroidectomy was the procedure done... The biopsy report came back as PAPILLARY CARCINOMA THYROID without extra thyroid spread.. What is the next step...To perform a completion Thyroidectomy or Radioablation?

Small thyroid carcinomas (< or = 1.5 cm), including microcarcinomas (< or = 1.0 cm) (n = 39), were found in 53 patients (41%) with a papillary (n = 130) and in 4 cases (4%) with a follicular (n = 110) carcinoma. The tumour was clinically manifested by palpability or by the presence of nodal metastases in 1/3 of patients. Concomitant diagnoses were colloid goitre (n = 24), cellular adenoma (n = 11), Graves' disease (n = 6), and Hashimoto's thyroiditis (n = 4). Nodal involvement, multifocal tumour, and extrathyroidal extent (pT4) were present in 9%, 19%, and 8% of cases respectively. Small follicular carcinomas were minimally invasive in all instances. According to the age-related prognostic TNM-classification, 52 patients (91%) were in the low risk category. 18% of the patients underwent uni- or bilateral partial lobectomy, 35% hemithyroidectomy, and 47% total thyroidectomy, according to the extent and nature of the concomitant benign disease, whereas hemi- or total thyroidectomy was performed in the patients with known cancer. Four of 5 patients with stage pT4 cancer and all patients with nodal involvement underwent total thyroidectomy with radioiodine (n = 8 [14%]). Postoperative morbidity was 0%. During the follow-up period of 1-17 (x = 5.5) years no tumour-related death and no serious recurrence was noted. One node recurrence was removed 1 year following treatment of a stage III pT1aN1b papillary carcinoma; the patient died 4 years later accidentally without residual disease. These results confirm that cases with a potentially favourable course can be defined and treated selectively by less radical measures. Small carcinomas (< or = 1.5 cm) belong to these favourable tumours with a cancer mortality rate of virtually 0%, and the aim of treatment is to prevent curable recurrences: node positivity is an important risk factor, and therefore radioiodine is reserved for carcinomas with nodal involvement and also for the occasional small pT4-tumour.
Materials and Methods :-
Thyroid tumor tissue was obtained at surgery from patients undergoing thyroidectomy (including hemi, subtotal, and total thyroidectomy). A pathologist dissected the tissue, and a small tumor tissue block from the dominant or suspicious nodule was snap-frozen in liquid nitrogen and stored at –80 C. The size and location of tumor samples were recorded in detail. All tumor samples were obtained with permission of and in accordance with the guidelines of our institutional review board, and informed consent was obtained from all patients. Histological classification was confirmed, the diagnosis was obtained from the final pathology report, and this diagnosis was reviewed and confirmed by an endocrine pathologist.

RNA extraction, purification, labeling, and hybridization

The methods described by Barden et al. (20) were employed for RNA extraction, purification, labeling, and hybridization. In brief, frozen tumor tissue was homogenized by sonication in TRIzol reagent (Invitrogen, Carlsbad, CA), and total RNA was prepared according to the manufacturer’s specifications. A total of 42 samples were analyzed by gene chip array (GeneChip Hu95 array, Affymetrix, Inc., Santa Clara, CA). The carcinoma samples included seven PTC and seven FVPTC. The benign samples consisted of 14 FA and seven hyperplastic nodules. An additional seven unknown samples were processed (blinded to preparer). All samples were processed in the same manner following the Affymetrix protocol. cDNA was synthesized from 8 µg sample RNA using T7 (dT)24 primer (GENSET Corp., La Jolla, CA). Second strand cDNA was then produced and purified. Biotin-labeled cRNA was made and used for hybridization to the Affymetrix oligonucleotide arrays. A sample aliquot was first hybridized to an Affymetrix test chip to confirm that the cRNA quality was adequate. All samples were of good quality. After staining with streptavidin-phycoerythrin, the chips were scanned in an HP ChipScanner (Affymetrix, Inc.) to detect hybridization signals.

Data analysis

The data were analyzed using MicroArray Suite version 5.0 (Affymetrix, Inc.). The intensity of each probe set of the array was captured, and the average intensity was calculated. Quantitative expression levels were calculated using intrachip-positive controls. Normalization of data was performed to account for variability in hybridization among duplicate probe sets and other hybridization artifacts. Transcripts were designated reliably detected (present) or not detected (absent) using the above analysis.

Data analysis was performed to identify genes that were differentially expressed between the papillary carcinoma (PTC and FVPTC) and benign groups (FA and hyperplasia). Data from the 21 benign tumors and 14 carcinomas that comprised the training set were used. First, the data were screened to identify signals counted as present by the Affymetrix software. These results were exported to GeneSpring (Silicon Genetics, Redwood City, CA), then analyzed with a parametric t test and multiple testing correction (Benjamini and Hochberg False Discovery Rate, with the P value set at <0.05), producing a gene list of 1149 genes differentially expressed. This list of 1149 differentially expressed genes was then used for unsupervised hierarchical clustering and statistical analysis. Cluster analysis was used to group the tumors based upon their similarities measured across the expression of 1149 genes.

To determine whether FVPTC could be differentiated from benign thyroid nodules, a second analysis, comparing only FVPTC tumors to benign thyroid nodules, was performed to identify genes differentially expressed between these groups. The data were exported to GeneSpring (Silicon Genetics) and using a nonparametric t test with a P value set at less than 0.01, the data were screened to produce a gene list of 843 differentially expressed genes between FVPTC and benign lesions. Finally, a similar analysis was performed to compare PTC to benign lesions. A total of 483 genes were differentially expressed between PTC and benign lesions. As described above, these gene lists were used for unsupervised hierarchical clustering and statistical analysis.

Evaluation of unknown samples

Once the hierarchical cluster analysis was established using gene expression profiles of differentially expressed genes in 35 tumors, the same analysis was performed on seven thyroid tumors (one PTC, four FVPTC, and two hyperplastic nodules) with investigators blinded to the final diagnosis. Gene profiles of the seven unknown tumors were produced using the 1149 differentially expressed genes for comparison. The unknown sample profiles were then added to the original 35 samples to create a combined group of 42 samples, which then underwent an unsupervised hierarchical clustering analysis.

To confirm the validity of the subset analysis of FVPTC vs. benign tumors, the unknown samples’ individual gene profiles were analyzed (excluding the one classical PTC), using the 843 differentially expressed genes produced by the analysis of FVPTC vs. benign tumors. The gene profiles of unknown samples combined with the test set (FVPTC vs. benign) samples underwent an unsupervised hierarchical cluster analysis, producing a dendrogram for the 34 samples. This same technique was repeated to analyze the PTC vs. benign tumor gene list. Unknown samples’ gene expression profiles were analyzed (excluding the four FVPTC) using the gene profile for 438 genes differentially expressed in the PTC vs. benign analysis. Once again the unknown samples were combined with the PTC vs. benign samples, and an unsupervised hierarchical clustering was performed. A dendrogram of the 31 samples (PTC vs. benign plus unknowns) was produced.

Semiquantitative RT-PCR

To verify the results of the Affymetrix gene chip array, a total of five genes were chosen that had expression levels with more than 2-fold difference, were implicated in the molecular pathogenesis of cancer, and had readily available primers or were made from the known mRNA sequences using Primer3 (21). One microgram of sample RNA was reverse transcribed with oligo(dT) primer in a total volume of 50 µl. A 1-µl aliquot of cDNA was used for PCR, and the product was electrophoresed in a 2.0% agarose gel and visualized with ethidium bromide and UV light. The band intensity for each sample was calculated using EagleSight software (version 3.2, Stratagene, La Jolla, CA), and a ratio of the intensity of the gene of interest to that of the housekeeping gene was calculated for each sample. These normalized intensity levels were then analyzed using a t test. The genes and primers are listed in Table 1.  (+ info)

Does anybody here know more about papillary carcinoma?

I had a thyroidectomy a couple of weeks ago & the biopsy showed that it'a a papillary carcinoma.I'm so paranoid.What should i do? Any information regarding this type of cancer will be very much appreciated.

Hi, I had that too! May '06 was my TT. I have two great sites for you....www.thyca.org is the national thyroid cancer site, and health.groups.yahoo.com/group/thyca is the "chat" room that I belong to where you can ask questions and get info and tons of support.
Always get copies of all your paperwork, including the surgeon's report. Get a good endocronologist. Your goal after RAI (radiation) will be to have a low TSH of .1 or lower...NOT "normal" (that is for people with thyroids, and many doctors do not know that) and if you are having RAI, you should go on the LID (low iodine diet) for two weeks before hand to help make your thyroid cancer cells hungry to eat up the radiation. Cancer is scary- and don't let you have anyone tell you "it's the good kind". it does have a very good long term prognosis....but you must be vigalant about it for the rest of you life. You will love these sites, and I look forward to seeing you in the thyca health group on line. good luck.  (+ info)

How do I get rid of Giant Papillary Conjunctivitis?

Is their anything I can do to make it go away faster? Please list things I can do (Don't list wear contacts less...I know that now!!!!).

yep. stop wearing lenses, and/or switching to dailies, getting on Rx meds like alrex and patanol

i have a recent blog entry about it:

http://blog.360.yahoo.com/blog-wSz1Uw8haa.._wmbA0eEWaW4  (+ info)

I have been diagnosed with Papillary Thyroid Cancer. What are dangers of radioactive iodine dye treatment?

I am also going to have my entire thyroid removed before the iodine dye treatment is done. The iodine dye treatment is being done through an IV in my wrist. I will be completely off my synthroid.

I had papillary cancer also. Never had the radioactive iodine treatment, backed out of it because of fertility concerns. Which the doctor than consulted someone at Columbia University and found out I was right. It is temporary though. Other concerns are damage to your salivary glands, usually temporary but may be permanent. Sucking candies are recommended. Also there is a small chance of developing a secondary cancer even though the radiation is targeted at remaining thyroid cells.

It has been 5 years, and I have a new doctor who wants me to see a specialist to see if radioactive iodine treatment is needed. Also there is a drug you can take so you do not need to go off synthroid. Not all places use it.

My initial doctor never thought I needed radioactive iodine treatment, but every endocrinologist I see does.   (+ info)

1  2  3  4  5  

Leave a message about 'Cystadenocarcinoma, Papillary'

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.